Related Experiment Video

Updated: Oct 6, 2025

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats
09:25

An Immunological Model for Heterotopic Heart and Cardiac Muscle Cell Transplantation in Rats

Published on: May 8, 2020

8.1K

Outcomes after heart transplantation in patients with cardiac sarcoidosis

Rabea Asleh1,2, Alexandros Briasoulis3,4, Ilias Doulamis5

  • 1Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.

ESC Heart Failure
|January 15, 2022
PubMed

Insights

Heart transplantation outcomes for sarcoid cardiomyopathy are comparable to other non-ischemic cardiomyopathies. This study found similar mortality and rejection rates, indicating effective treatment strategies for sarcoid heart disease.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Immunology

Background:

  • Increasing incidence of sarcoidosis necessitating heart transplantation (HT).
  • Need to evaluate outcomes of isolated HT in sarcoid cardiomyopathy patients.
  • Comparison with non-ischaemic restrictive or dilated cardiomyopathy recipients.

Purpose of the Study:

  • To assess the outcomes of isolated heart transplantation in patients with sarcoid cardiomyopathy.
  • To compare these outcomes with recipients suffering from non-ischaemic restrictive or dilated cardiomyopathy.
  • To analyze mortality, rejection rates, and long-term survival.

Main Methods:

  • Analysis of the UNOS Registry (1990-2020) for adult HT recipients.
  • Grouping patients by diagnosis: sarcoidosis, non-ischaemic restrictive, and non-ischaemic dilated cardiomyopathy.
  • Utilizing Fine and Gray model for cumulative incidence of mortality and rejection, accounting for re-transplantation.
  • Logistic regression for rejection analysis and single-centre case review for long-term outcomes with sirolimus-based immunosuppression.

Main Results:

  • No significant difference in all-cause mortality at latest follow-up between sarcoidosis and non-ischaemic cardiomyopathies (aSHR 1.46, P=0.12 for dilated; aSHR 1.12, P=0.67 for restrictive).
  • Similar 1-year mortality rates observed across groups (aSHR 1.56, P=0.12 for dilated; aSHR 1.15, P=0.66 for restrictive).
  • No significant differences in 30-day mortality, treated acute rejection, or graft failure. Single-centre data showed excellent long-term outcomes with sirolimus.

Conclusions:

  • Short-term and long-term outcomes post-heart transplantation for sarcoid cardiomyopathy are similar to common non-ischaemic cardiomyopathies.
  • Current treatment strategies appear effective in managing sarcoid cardiomyopathy patients undergoing HT.
  • Further research into optimizing immunosuppression, like sirolimus-based regimens, may enhance long-term results.
Abstract

Keywords:
Cardiac sarcoidosisDilated cardiomyopathyHeart transplantationOutcomesRestrictive cardiomyopathy

More Related Videos

Optimization of the Cuff Technique for Murine Heart Transplantation14:01

Optimization of the Cuff Technique for Murine Heart Transplantation

Published on: June 26, 2020

9.5K
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
59
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
84
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
59
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
29
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
68
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
84